Malignant Pleural Effusion Market Forecast 2026–2030: Market Size, Trends And Growth Opportunities

Malignant Pleural Effusion Market Report

Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.

Malignant Pleural Effusion Market Growth From $5.05 Billion In 2026 To $6.52 Billion By 2030 At A CAGR Of 6.6%

The market for malignant pleural effusion has shown strong growth in recent years. It is anticipated to expand from $4.73 billion in 2025 to $5.05 billion in 2026, at a compound annual growth rate (CAGR) of 6.8%. This historical growth can be ascribed to elements such as the increasing prevalence of metastatic cancers, the limited array of curative treatment alternatives, the dependence on repeated thoracentesis for managing symptoms, the expansion of hospital-based cancer services, and the progressive adoption of pleurodesis techniques.

The malignant pleural effusion market is projected for substantial expansion over the next few years. It is expected to grow to $6.52 billion in 2030, achieving a compound annual growth rate (CAGR) of 6.6%. This anticipated growth during the forecast period stems from factors such as the global rise in cancer prevalence, innovations in pleural catheter technologies, an increased focus on outpatient and home-based care models, improved accuracy in diagnostic imaging, and a growing demand for treatments centered on enhancing quality of life. Prominent trends for this period encompass the expanded adoption of indwelling pleural catheters for long-term care, a rising preference for minimally invasive pleural interventions, greater integration of systemic cancer therapies into mpe management, an elevated emphasis on symptom relief and palliative care strategies, and the broadening application of imaging-guided diagnostic and therapeutic procedures.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=83236152&type=smp&name=Malignant%20Pleural%20Effusion%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Nov_PR

Malignant Pleural Effusion Market Opportunity Drivers: What’s Unlocking New Revenue Potential?

A surge in lung cancer diagnoses is anticipated to stimulate the expansion of the malignant pleural effusion market moving ahead. Lung cancer is characterized by the unchecked growth of atypical cells within the lungs, which can form masses and disrupt normal pulmonary function. The increasing incidence of lung cancer is primarily linked to smoking and tobacco usage, given that prolonged exposure to detrimental chemicals in cigarettes damages lung tissues, instigates genetic mutations, and fosters the uncontrolled proliferation of cancerous cells, significantly elevating the probability of developing the illness. Malignant pleural effusion signals advanced lung cancer progression by facilitating the spread of tumors within the pleural cavity, leading to aggravated respiratory impairment and a less favorable outlook. For example, in January 2023, according to the American Cancer Society Facts and Figures, a US-based professional organizations company, new cases of lung and bronchus cancer were estimated at 236,740 in 2022 and 238,340 in 2023, while estimated deaths amounted to 130,180 in 2022 and 127,070 in 2023. Consequently, the rising number of lung cancer cases is a key impetus for the growth of the malignant pleural effusion market.

Malignant Pleural Effusion Market Segment Analysis And Revenue Potential

The malignant pleural effusion market covered in this report is segmented –

1) By Treatment: Systemic Therapy, Therapeutic Thoracentesis, Thoracic Drainage And Pleurodesis, Indwelling Pleural Catheter

2) By Diagnosis: Pleural Fluid Cytology, Immunohistochemical Tests, Imaging Tests, Pleural Thoracentosis, Pleuroscopy, Pleural Biopsy

3) By End Users: Hospitals, Ambulatory Clinics, Other End Users

Subsegments:

1) By Systemic Therapy: Chemotherapy, Targeted Therapy, Immunotherapy

2) By Therapeutic Thoracentesis: Single-Time Thoracentesis, Repeated Thoracentesis

3) By Thoracic Drainage And Pleurodesis: Chemical Pleurodesis, Mechanical Pleurodesis

4) By Indwelling Pleural Catheter: Tunneled Pleural Catheter, Non-Tunneled Pleural Catheter

Malignant Pleural Effusion Market Innovation Trends Shaping Future Development

Leading firms in the malignant pleural effusion sector are prioritizing the creation of novel solutions, including fully-implantable automatic fluid-shunt devices, aimed at enhancing patient comfort and decreasing hospital attendance. Such a device is a surgically inserted medical instrument designed to autonomously divert surplus pleural fluid from the lungs into the abdomen or other regions, thereby alleviating dyspnea, minimizing the necessity for recurrent hospital interventions, and elevating the patient’s quality of life. As an illustration, in October 2023, Pleural Dynamics, a medical device firm located in the US, introduced its ACES Automatic Continuous Effusion Shunt System. This system consists of a durable, flexible pump chamber positioned beneath the skin between the ribs, featuring one catheter situated in the pleural cavity and a second in the peritoneal cavity. With each breath the patient takes, the internal pump extension undergoes compression and decompression between neighboring ribs, propelling fluid from the pleural cavity into the abdomen for reabsorption; additionally, the system offers manual activation through an external compression mechanism. Its primary attributes encompass a fully implantable configuration, the absence of external drainage tubes or suction bottles, an automatic pumping function powered by breathing, a short hospital stay for its placement, and ongoing symptom alleviation for recurring effusions.

Malignant Pleural Effusion Market Key Players Shaping Industry Direction

Major companies operating in the malignant pleural effusion market are Becton Dickinson and Company, Cook Medical LLC, Merit Medical Systems Inc, Argon Medical Devices Inc, B Braun SE, Medtronic plc, Smiths Medical, Teleflex Incorporated, Cardinal Health Inc, Getinge AB, AngioDynamics Inc, Rocket Medical plc, Redax SpA, Atrium Medical Corporation, PolyMedicure Ltd, Troge Medical GmbH, Vygon SA, ICU Medical Inc, ConvaTec Group plc, Baxter International Inc

View The Full Malignant Pleural Effusion Market Report:

https://thebusinessresearchcompany.com/report/malignant-pleural-effusion-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Nov_PR

Malignant Pleural Effusion Market Regional Analysis And Top Geography

North America was the largest region in the malignant pleural effusion market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the malignant pleural effusion market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model